Our Posts

In a significant legal decision, Johnson & Johnson and its subsidiary DePuy Orthopaedics were found liable for defective hip implants, resulting in a jury awarding millions in damages to ten plaintiffs. The verdict, delivered in Texas on November 16, 2017, included compensatory, future, and punitive damages. This case is part of ongoing litigation against Johnson & Johnson for their Pinnacle line of metal-on-metal hip implants, which have caused severe health issues for patients. The jury's decision underscores the company's failure to address known defects and misleading marketing practices.

Hip replacement surgery involves replacing a damaged hip joint with an implant, often due to arthritis. The Pinnacle hip implant, made by DePuy Orthopaedics, is designed for younger patients and offers various material options, including metal-on-metal, which has faced legal issues due to complications like metallosis. Despite numerous lawsuits and reported injuries, the Pinnacle implant has not been recalled. Legal actions have been consolidated into Multidistrict Litigation, with significant verdicts against Johnson & Johnson. Patients experiencing issues are advised to seek legal counsel to explore compensation options.

Thousands of patients are at risk due to defective batteries in St. Jude Medical's implantable cardioverter defibrillators (ICDs). These batteries can short circuit and deplete rapidly, leaving patients without time to seek medical advice. Despite knowing about the defect since 2011, St. Jude did not inform the FDA until 2016, leading to a recall. Parker Waichman LLP is pursuing lawsuits against the manufacturers to seek compensation for affected individuals. The firm offers a free case review for those impacted by these defective ICDs.

A federal judge has ordered DePuy Orthopaedics, a Johnson & Johnson subsidiary, to provide key documents in a multidistrict litigation involving over 900 cases. The company is accused of hiding complications related to its Pinnacle metal-on-metal hip implants. Judge Ed Kinkeade's ruling requires DePuy to submit compliance monitoring reports, which will be reviewed by a court-appointed overseer and shared with plaintiffs. The reports are crucial for understanding the marketing and promotional practices of the Pinnacle system, which allegedly caused severe health issues due to metal particle release.

Knee replacements are common, but they carry risks such as infection. A man who had both knees replaced developed a severe infection, leading to leg amputation. He is suing his healthcare providers and the manufacturer of the Bair Hugger, a device used during surgery, alleging it caused the infection. The Bair Hugger warms patients during surgery and is used in many hospitals. Over 4,000 patients claim it led to infections. Legal actions are being pursued for compensation related to these infections.

The FDA reported setbacks in a clinical trial for Johnson & Johnson's type 2 diabetes drug, canagliflozin, due to dangerous side effects. The drug, which may increase bad cholesterol and heart risks, also showed adverse effects on kidneys and increased fungal and bacterial growth. These issues could hinder its approval, as the FDA requires new diabetes drugs to avoid heart-related complications. The final review is set for June 10. If approved, canagliflozin will be marketed as Invokana, joining the SGLT2 inhibitors class.

A lawsuit has been filed against Arizant, a subsidiary of 3M, over the Bair Hugger surgical warming blanket, alleging it introduced dangerous pathogens into a surgical site, causing a MRSA infection during a hip implant revision. The device, used in 90% of major U.S. surgeries, is claimed to be risky for joint surgeries, potentially contributing to numerous infections. The plaintiff underwent multiple surgeries due to the infection, resulting in permanent damage. The lawsuit accuses Arizant and 3M of concealing the device's risks and failing to conduct adequate safety surveillance.

Johnson & Johnson and its subsidiary, DePuy Orthopedics, are facing a trial over allegations of deceptive marketing of their metal-on-metal Pinnacle hip implants. Plaintiffs claim J&J bypassed regulatory reviews and misled doctors about the device's safety, resulting in complications like metal poisoning and tissue damage. The trial is part of a larger multidistrict litigation involving 8,500 lawsuits. Previously, a $500 million verdict was awarded, later reduced to $150 million. The current case, under California law, could lead to a significant verdict without a punitive damages cap.

A Virginia woman has filed a lawsuit claiming her DePuy Pinnacle metal-on-metal hip implant is defective, causing her lifelong mental and physical pain. The lawsuit, filed in the U.S. District Court for the Northern District of Texas, is part of a larger group of similar claims against DePuy Orthopaedics, a division of Johnson & Johnson. The woman, represented by Parker Waichman LLP, alleges the implant's defects led to metal poisoning and other health issues, necessitating ongoing medical care and potential revision surgeries.

Parker Waichman LLP is investigating lawsuits for individuals with primary biliary cholangitis (PBC) who suffered liver injuries after taking Ocaliva. Ocaliva, used to treat PBC, has been linked to serious liver injuries when taken daily instead of weekly, prompting the FDA to require a boxed warning. Patients with moderate to severe PBC are at risk, and those affected may be entitled to compensation. Parker Waichman LLP has a strong track record in securing settlements and offers free consultations for potential claims.

Sodium-Glucose co-Transporter 2 (SGLT2) inhibitors, used to manage Type 2 diabetes, have been linked to severe side effects, including diabetic ketoacidosis, kidney damage, and amputations. Initially popular, these drugs now require caution due to these risks. Many patients, unaware of the dangers, have suffered injuries and filed lawsuits against manufacturers like Johnson & Johnson and AstraZeneca. Parker Waichman LLP is representing affected individuals, seeking compensation for injuries caused by these medications. The FDA has issued warnings, including a "Black Box Warning" for Invokana, highlighting the need for careful consideration of these drugs.

The Taxotere permanent hair loss multidistrict litigation (MDL) is advancing with over 700 lawsuits consolidated in the U.S. District Court, Eastern District of Louisiana. Plaintiffs claim that Sanofi-Aventis failed to warn about the risk of permanent hair loss associated with Taxotere, a chemotherapy drug. Despite evidence from studies and reports, the U.S. label was not updated until 2015. The MDL aims to streamline proceedings, with each case treated individually. Parker Waichman LLP represents many plaintiffs, offering free consultations for those affected.

Parker Waichman LLP is actively involved in litigation against Bayer HealthCare Pharmaceuticals, Inc. over the Mirena IUD, which has been linked to complications such as pseudotumor cerebri and intracranial hypertension. The firm accuses Bayer of deceptive advertising, which overstated the benefits and minimized the risks of Mirena. The FDA had previously warned Bayer about misleading claims in their ads. Parker Waichman is accepting new cases and offers free consultations for those affected by these complications, aiming to help women seek compensation.

3M is facing a lawsuit over its Bair Hugger surgical warming blanket, which allegedly caused burn injuries, unlike most claims that focus on infections. The Bair Hugger, used in over 80% of U.S. hospitals, maintains body temperature during surgery by pumping warm air into a blanket. The plaintiff claims the device is defectively designed, seeking compensation from 3M and Arizant Healthcare. Over 800 lawsuits have been filed, primarily alleging infections, with a multidistrict litigation established in Minnesota to handle these cases.

If you or a loved one experienced a heart attack, stroke, or other serious medical event after using Actemra, contact Parker Waichman LLP for legal assistance. Actemra was marketed as a safe treatment for rheumatoid arthritis, but may have serious risks. Prompt action is crucial to protect your rights. Call 1-800-YOURLAWYER (1-800-968-7529) or fill out the consultation form for a callback from an experienced lawyer to discuss your options.

Medline Industries Inc., a Chicago-based medical supplier, faces lawsuits from 18 plaintiffs over counterfeit surgical mesh sold under the C. R. Bard/Davol brand. The mesh, used for hernia repairs, was actually made by a company in Delhi, India. The FDA warned about the mesh's sterility and performance issues, leading to a recall. Medline is named in eight lawsuits for selling "defective and unreasonably dangerous" mesh. Medline is suing Ram Medical and its insurer for legal expenses related to these lawsuits.

Nearly 700 lawsuits have been filed in the Bair Hugger warming blanket multidistrict litigation (MDL) in Minnesota, alleging the system causes severe infections. The court requires plaintiffs to complete a "Plaintiff Fact Sheet" within 90 days. The Bair Hugger system, used to maintain body temperature during surgeries, allegedly leads to deep joint infections, necessitating additional surgeries or amputations. The MDL process consolidates cases for pretrial proceedings, aiming to streamline discovery and avoid inconsistent rulings. The system, approved by the FDA in 1988, has been used in over 200 million patients.

Parker Waichman LLP, a New York-based law firm, represents diabetes patients harmed by empagliflozin, a drug linked to severe side effects like amputations. Empagliflozin, marketed as Jardiance, is used for Type-2 diabetes but has been associated with increased amputation risks. The European Medical Association issued warnings about these risks, leading to mandatory label updates. Parker Waichman LLP offers experienced legal representation for those affected, emphasizing their success in pharmaceutical litigation and commitment to securing compensation without upfront costs.

Parker Waichman LLP discusses the ongoing lawsuits related to SGLT2 inhibitors, diabetes drugs linked to severe injuries like limb amputation and kidney damage. These drugs, including Invokana and Farxiga, have led to numerous lawsuits against manufacturers such as Johnson & Johnson and AstraZeneca. The cases are part of a Multi-district Litigation in New Jersey, with no settlements yet. Parker Waichman LLP, experienced in drug defect cases, offers legal representation to affected individuals, aiming to secure compensation for their injuries.

ACE inhibitors, used to treat high blood pressure, have been linked to an increased risk of lung cancer. A study in the British Medical Journal found a 14% higher risk of lung cancer in ACE inhibitor users compared to those using angiotensin II receptor blockers, rising to 31% after 10 years. This risk may be due to the accumulation of bradykinin and substance P in the lungs. Common side effects of ACE inhibitors include rash, headache, and dry cough, with severe effects like angioedema and kidney failure. Parker Waichman, LLP is investigating potential lawsuits related to these findings.

Regulators in the UK, EMA, and FDA have warned that Invokana (canagliflozin), a type 2 diabetes medication, may increase the risk of lower limb amputations. This risk is particularly noted in patients with poor diabetes control and cardiovascular issues. Healthcare professionals are advised to monitor patients for foot problems and consider discontinuing the drug if necessary. The FDA has added a boxed warning to Invokana and Invokamet labels. Legal consultations are available for those considering lawsuits related to Invokana's side effects.

Parker Waichman LLP is a national plaintiffs' law firm specializing in maximizing financial compensation for clients affected by medical malpractice and defective products. They focus on cases involving ulcerative colitis patients who experienced severe side effects, such as sepsis and blood clotting, after taking corticosteroids before surgery. The firm emphasizes the importance of legal representation, noting that clients with attorneys typically receive higher settlements. They operate on a contingency fee basis, ensuring clients pay nothing upfront. With over $2 billion recovered for clients, Parker Waichman LLP is committed to achieving justice and substantial compensation for those harmed.

A lawsuit was filed on March 21, 2017, by 28 women against Bayer HealthCare, alleging that the company failed to warn them of serious health risks associated with the Essure birth control device. The case, initially in the Superior Court of Alameda County, seeks to be moved to federal court. Plaintiffs claim Essure caused complications like device migration, organ perforation, and chronic pain. Despite FDA approval in 2002, serious side effects emerged later, leading to a black box warning. The lawsuit accuses Bayer of misleading marketing and inadequate risk disclosure.

The first trial over allegations against Johnson & Johnson's DePuy Pinnacle hip devices has begun, focusing on claims of defective design leading to premature failures and metal debris entering patients' bloodstreams. The trial, overseen by U.S. District Judge Ed Kinkeade in Dallas, is a bellwether case among over 6,000 similar lawsuits. The plaintiff, a graphic artist, seeks damages for physical injuries, loss of earnings, and emotional distress. Johnson & Johnson previously recalled 93,000 ASR hip devices due to high failure rates, with concerns about cancer risks and genetic damage from metal-on-metal hips.